Description de l'entreprise
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain disease. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Conseil d'administration & Conseil de surveillance
| PDG |
| Dr. Deborah Dunsire |
| Conseil d'administration |
| Anders Götzsche, Dr. Johan Luthman, Elise Hauge, Jacob Tolstrup, Keld Flintholm Jørgensen, Lars Bang |
| Conseil de surveillance |
| Lars Rasmussen, Dorothea Wenzel, Henrik Sindal Jensen, Jeffrey Berkowitz, Jeremy M. Levin, Lars Holmqvist, Lene Skole-Sørensen, Ludovic Tranholm Otterbein, Rikke Kruse Andreasen, Santiago Arroyo |
Données de l'entreprise
| Nom: |
H. Lundbeck A/S |
| Adresse: |
Ottiliavej 9,DK-2500 Valby |
| Téléphone: |
+45-3630-1311 |
| Fax: |
+45-3630-1940 |
| Courriel: |
information@lundbeck.com
|
| Internet: |
www.lundbeck.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
31.00% |
| IPO date: |
- |
Relations avec les investisseurs
| Nom: |
Palle Holm Olesen |
| Téléphone IR: |
+45-3643-2426 |
| IR-Fax: |
- |
| E-mail IR: |
investor@lundbeck.com
|
